Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Smart Eye in conjunction with a rights issue of MSEK 324.
Mandate

Vinge has advised Smart Eye in conjunction with a rights issue of MSEK 324.

February 20, 2023 Capital Markets and Public M&A

Vinge has advised Smart Eye Aktiebolag (First North Growth Market) in connection with its fully secured rights issue which provided Smart Eye with MSEK 324 before transaction costs. The issue was fully subscribed and no guarantee commitments had to be utilised.

Vinge's team primarily mainly of Anders Strid, Oscar Lunde (project manager), Amelia Rihs, Fredrik Löwenclou and corporate assistant Daniela Maniscalchi. Carnegie acted as financial advisor to Smart Eye.

Read more here

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

 Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

 Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025